Table 1.
Women with cT1-4c, cN1-3, HR+ Invasive Lobular Carcinoma Who Received Neoadjuvant Endocrine Therapy or Chemotherapy, National Cancer Data Base, 2004-2014 (N=5942)
| All patients (N=5942) n (%)a | Neoadjuvant endocrine therapy (N=855) n (%)a | Neoadjuvant chemotherapy (N=5087) n (%)a | P-Valuef | |
|---|---|---|---|---|
| Age (years) | <0.001 | |||
| ≥50 | 3978 (66.9%) | 783 (91.6%) | 3195 (62.8%) | |
| <50 | 1964 (33.1%) | 72 (8.4%) | 1892 (37.2%) | |
| Median (IQR) | 55.0 (47.0-64.0) | 70.0 (59.0-78.0) | 54.0 (46.0-62.0) | <0.001 |
| Race | 0.79 | |||
| White | 5018 (84.4%) | 729 (85.3%) | 4289 (84.3%) | |
| Black | 682 (11.5%) | 97 (11.3%) | 585 (11.5%) | |
| Other | 188 (3.2%) | 24 (2.8%) | 164 (3.2%) | |
| Ethnicity | 0.007 | |||
| Hispanic | 364 (6.1%) | 35 (4.1%) | 329 (6.5%) | |
| Non-Hispanic | 5324 (89.6%) | 783 (91.6%) | 4541 (89.3%) | |
| Charlson-Deyo comorbidity score | <0.001 | |||
| 0 | 5175 (87.1%) | 674 (78.8%) | 4501 (88.5%) | |
| 1 | 638 (10.7%) | 137 (16.0%) | 501 (9.8%) | |
| ≥2 | 129 (2.2%) | 44 (5.1%) | 85 (1.7%) | |
| Clinical T classification | <0.001 | |||
| 1 | 715 (12.0%) | 139 (16.3%) | 576 (11.3%) | |
| 2 | 2254 (37.9%) | 338 (39.5%) | 1916 (37.7%) | |
| 3 | 2344 (39.4%) | 261 (30.5%) | 2083 (40.9%) | |
| 4 | 629 (10.6%) | 117 (13.7%) | 512 (10.1%) | |
| Pathological T classification | <0.001 | |||
| 0 | 184 (3.1%) | 1 (0.1%) | 183 (3.6%) | |
| 1 | 1311 (22.1%) | 137 (16.0%) | 1174 (23.1%) | |
| 2 | 1802 (30.3%) | 337 (39.4%) | 1465 (28.8%) | |
| 3 | 1320 (22.2%) | 220 (25.7%) | 1100 (21.6%) | |
| 4 | 210 (3.5%) | 55 (6.4%) | 155 (3.0%) | |
| X | 947 (15.9%) | 87 (10.2%) | 860 (16.9%) | |
| Clinical N classification | 0.26 | |||
| 1 | 4626 (77.9%) | 683 (79.9%) | 3943 (77.5%) | |
| 2 | 919 (15.5%) | 117 (13.7%) | 802 (15.8%) | |
| 3 | 397 (6.7%) | 55 (6.4%) | 342 (6.7%) | |
| Pathological N classification | <0.001 | |||
| 0 | 753 (12.7%) | 69 (8.1%) | 684 (13.4%) | |
| 1 | 1771 (29.8%) | 266 (31.1%) | 1505 (29.6%) | |
| 2 | 1416 (23.8%) | 208 (24.3%) | 1208 (23.7%) | |
| 3 | 1027 (17.3%) | 193 (22.6%) | 834 (16.4%) | |
| X | 858 (14.4%) | 99 (11.6%) | 759 (14.9%) | |
| Grade | <0.001 | |||
| 1 | 924 (15.6%) | 211 (24.7%) | 713 (14.0%) | |
| 2 | 3209 (54.0%) | 467 (54.6%) | 2742 (53.9%) | |
| 3 | 999 (16.8%) | 77 (9.0%) | 922 (18.1%) | |
| Surgery type | <0.001 | |||
| Lumpectomy | 1143 (19.2%) | 235 (27.5%) | 908 (17.8%) | |
| Mastectomy | 4799 (80.8%) | 620 (72.5%) | 4179 (82.2%) | |
| Median no. of nodes examined (IQR) | 13.0 (8.0-18.0) | 13.0 (7.0-18.0) | 13.0 (8.0-18.0) | 0.07 |
| Median no. of positive nodes (IQR) | 3.0 (1.0-8.0) | 4.0 (1.0-9.0) | 3.0 (1.0-8.0) | <0.001 |
| Treated with radiation post-lumpectomyb | <0.001 | |||
| No | 145 (12.7%) | 63 (26.8%) | 82 (9.0%) | |
| Yes | 998 (87.3%) | 172 (73.2%) | 826 (91.0%) | |
| Treated with radiation post-mastectomyc | <0.001 | |||
| No | 1051 (21.9%) | 248 (40.0%) | 803 (19.2%) | |
| Yes | 3748 (78.1%) | 372 (60.0%) | 3376 (80.8%) | |
| Treated with adjuvant endocrine therapyd | - | |||
| No | 536 (9.0%) | - | 536 (10.5%) | |
| Yes | 4380 (73.7%) | - | 4380 (86.1%) | |
| Treated with adjuvant chemotherapye | - | |||
| No | 563 (9.5%) | 563 (65.8%) | - | |
| Yes | 280 (4.7%) | 280 (32.7%) | - | |
| Year of diagnosis | <0.001 | |||
| 2004 | 247 (4.2%) | 21 (2.5%) | 226 (4.4%) | |
| 2005 | 265 (4.5%) | 21 (2.5%) | 244 (4.8%) | |
| 2006 | 328 (5.5%) | 40 (4.7%) | 288 (5.7%) | |
| 2007 | 392 (6.6%) | 50 (5.8%) | 342 (6.7%) | |
| 2008 | 460 (7.7%) | 57 (6.7%) | 403 (7.9%) | |
| 2009 | 521 (8.8%) | 88 (10.3%) | 433 (8.5%) | |
| 2010 | 685 (11.5%) | 103 (12.0%) | 582 (11.4%) | |
| 2011 | 654 (11.0%) | 121 (14.2%) | 533 (10.5%) | |
| 2012 | 725 (12.2%) | 116 (13.6%) | 609 (12.0%) | |
| 2013 | 762 (12.8%) | 112 (13.1%) | 650 (12.8%) | |
| 2014 | 903 (15.2%) | 126 (14.7%) | 777 (15.3%) | |
| Income level ($) | 0.001 | |||
| <$35,000 | 1429 (24.0%) | 241 (28.2%) | 1188 (23.4%) | |
| ≥$35,000 | 4287 (72.1%) | 574 (67.1%) | 3713 (73.0%) | |
| Insurance status | <0.001 | |||
| Private | 3682 (62.0%) | 256 (29.9%) | 3426 (67.3%) | |
| Government | 1966 (33.1%) | 564 (66.0%) | 1402 (27.6%) | |
| Not Insured | 181 (3.0%) | 15 (1.8%) | 166 (3.3%) | |
| Education level | 0.73 | |||
| >80% High School Graduation Rate | 3789 (63.8%) | 536 (62.7%) | 3253 (63.9%) | |
| ≤80% High School Graduation Rate | 1927 (32.4%) | 279 (32.6%) | 1648 (32.4%) | |
| Facility type | 0.72 | |||
| Academic | 2333 (39.3%) | 334 (39.1%) | 1999 (39.3%) | |
| Integrated Network | 747 (12.6%) | 116 (13.6%) | 631 (12.4%) | |
| Comprehensive | 2450 (41.2%) | 351 (41.1%) | 2099 (41.3%) | |
| Community | 412 (6.9%) | 54 (6.3%) | 358 (7.0%) | |
| Facility location | 0.18 | |||
| Midwest | 1540 (25.9%) | 215 (25.1%) | 1325 (26.0%) | |
| Northeast | 1293 (21.8%) | 199 (23.3%) | 1094 (21.5%) | |
| South | 2224 (37.4%) | 299 (35.0%) | 1925 (37.8%) | |
| West | 885 (14.9%) | 142 (16.6%) | 743 (14.6%) |
a
Percentages are out of total population counts unless otherwise indicated and may not add up to 100 due to rounding or missing values.
b
Percentages represent rates of radiation receipt among patients receiving lumpectomy.
c
Percentages represent rates of radiation receipt among patients receiving mastectomy.
d
Adjuvant endocrine therapy rates are only summarized for patients who did not receive neoadjuvant endocrine therapy.
e
Adjuvant chemotherapy rates are only summarized for patients who did not receive neoadjuvant chemotherapy.
f
P-values for categorical variables are from chi-square tests. P-values from continuous variables are from pooled t-tests.
HR+: hormone receptor-positive. IQR: interquartile range.